Klimopath Labor F Klinische U Molekulare Pathologie
Klimopath Labor F Klinische U Molekulare Pathologie is recorded as a service provider in 3 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 3 of 3 trials · Latest update first
A randomised, double-blind, double-dummy, multicentre, phase III, non inferiority trial of an oral mesalazine formulation in patients with active mild to moderate ulcerative colitis for the induction of remission.
Sponsor Faes Farma S.A.
- Start (EU)
- Latest update
- Estimated end
A multicentre, single arm trial on contraceptive efficacy, safety and tolerability of LVDS (Levonorgestrel Vaginal Delivery System) during 13 cycles.
Sponsor Chemo Research S.L.
- Start (EU)
- Latest update
- Estimated end
- Not reported
A pivotal, multicentre, randomised, open-label, parallel-group trial on contraceptive efficacy, safety and tolerability of LVDS (Levonorgestrel Vaginal Delivery System) during 9 cycles in comparison with Desogestrel tablets 0.075 mg.
Sponsor Chemo Research S.L.
- Start (EU)
- Latest update
- Estimated end
- Not reported
Questions about this trial experience
What services are recorded for Klimopath Labor F Klinische U Molekulare Pathologie?
The 2026-10-09 snapshot links Klimopath Labor F Klinische U Molekulare Pathologie to 3 distinct CTIS trials. Recorded services include Laboratory services. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for Klimopath Labor F Klinische U Molekulare Pathologie?
The most frequently recorded therapeutic areas are Gastroenterology, Immunology. Recorded phases include Phase 3. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to Klimopath Labor F Klinische U Molekulare Pathologie conducted?
The linked trials record locations in 10 countries, including Czechia, Spain, Hungary, Poland, Slovakia. These are trial locations, not confirmed office locations or countries where Klimopath Labor F Klinische U Molekulare Pathologie delivered services.
What can this page tell me about Klimopath Labor F Klinische U Molekulare Pathologie's trial experience?
Browse 3 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. No trial-level operational findings are recorded in this snapshot. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 1 recorded name variant under Klimopath Labor F Klinische U Molekulare Pathologie. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- Klimopath Labor F Klinische U Molekulare Pathologie